2-(3'-chlorobenzoyl)-3H-benzo[f]chromen-3-one | 1148118-62-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并吡喃类
• 英文名称: 2-(3'-chlorobenzoyl)-3H-benzo[f]chromen-3-one
• 英文别名: 2-(3-chloro-benzoyl)-benzo[f]chromen-3-one；2-(3-Chlorobenzoyl)benzo[f]chromen-3-one
• CAS: 1148118-62-0
• 化学式: C₂₀H₁₁ClO₃
• 分子量: 334.759
• InChiKey: CDJQLZNYMNDPSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3'-chlorobenzoyl)-3H-benzo[f]chromen-3-one 在 吡啶 、 sodium tetrahydroborate 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 6-(3'-chlorophenyl)-5-[2''-hydroxynaphthyl-(1'')-methyl]-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one
  参考文献：
  名称：

  Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: Coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile

  摘要：

  In this report we describe the synthesis and biological characterization of two series of sirtuins' inhibitors (SIRTi), designed as simplification products of the previously reported SIRT1-selective inhibitor MC2141 (4). In the first series (5a-t) we report a number of 2-substituted-1,2-dihydrobenzo[f] chromen-3-ones with a marked selectivity for the inhibition of SIRT2 over SIRT1. Some of such derivatives showed also high pro-apoptotic (5i and 5l) and/or cytodifferentiating (5d, 5i, and 5o) properties in a human leukemia cell line (U937). The second group of SIRTi (6a-q) is characterized by some analogues of cambinol (3), a well known SIRTi active against the Burkitt lymphoma. Such compounds, differently from the unselective prototype, are endowed with a selective inhibition of SIRT1 over SIRT2, and, in some cases (6j, 6k, and 6q), are more efficient than 3 to induce apoptosis in U937 cells. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.01.025
• 作为产物：
  描述：

  2-羟基-1-萘甲醛 、 (3-氯苯甲酰)乙酸乙酯 在 哌啶 作用下， 以 乙醇 为溶剂， 以87%的产率得到2-(3'-chlorobenzoyl)-3H-benzo[f]chromen-3-one
  参考文献：
  名称：

  Novel Cambinol Analogs as Sirtuin Inhibitors: Synthesis, Biological Evaluation, and Rationalization of Activity

  摘要：

  The tenovins and cambinol are two classes of sirtuin inhibitor that exhibit antitumor activity in preclinical models. This report describes modifications to the core structure of cambinol, in particular by incorporation of substitutents at the N1-position, which lead to increased potency and modified selectivity. These improvements have been rationalized using molecular modeling techniques. The expected functional selectivity in cells was also observed for both a SIRT1 and a SIRT2 selective analog.

  DOI：

  10.1021/jm8014298

文献信息

• [EN] PYRIMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE<br/>[FR] DÉRIVÉS DE PYRIMIDE ET LEUR USAGE PHARMACEUTIQUE
  申请人：UNIV DUNDEE

  公开号：WO2010038043A1

  公开（公告）日：2010-04-08

  The invention provides a compound according to formula (I): wherein: X is O or S; Y is O or S; each Ar and Ar' is independently a mono-, bi- or tricyclic aryl or heteroaryl group optionally substituted with one or more substituents selected from halo, alkyl, aryl, heteroaryl, hydroxyl, nitro, amino, alkoxy, alkylthio, cyano, thio, ester, acyl and amido; each R2 is independently hydrogen, halo, alkyl, aryl, heteroaryl, hydroxyl, nitro, amino, alkoxy, alkylthio, cyano and thio; and R1 is as defined herein, or a physiologically acceptable salt, solvate, ester, amide or other physiologically functional derivative thereof.

  该发明提供了一个符合以下式（I）的化合物：其中：X为O或S；Y为O或S；每个Ar和Ar'独立地是一个单环、双环或三环芳基或杂芳基，可选地取代一个或多个卤素、烷基、芳基、杂芳基、羟基、硝基、氨基、烷氧基、烷硫基、氰基、硫基、酯基、酰基和酰胺基；每个R2独立地是氢、卤素、烷基、芳基、杂芳基、羟基、硝基、氨基、烷氧基、烷硫基、氰基和硫基；R1如本文所定义，或其生理上可接受的盐、溶剂合物、酯、酰胺或其他生理功能衍生物。
• Novel Cambinol Analogs as Sirtuin Inhibitors: Synthesis, Biological Evaluation, and Rationalization of Activity
  作者：Federico Medda、Rupert J. M. Russell、Maureen Higgins、Anna R. McCarthy、Johanna Campbell、Alexandra M. Z. Slawin、David P. Lane、Sonia Lain、Nicholas J. Westwood

  DOI：10.1021/jm8014298

  日期：2009.5.14

  The tenovins and cambinol are two classes of sirtuin inhibitor that exhibit antitumor activity in preclinical models. This report describes modifications to the core structure of cambinol, in particular by incorporation of substitutents at the N1-position, which lead to increased potency and modified selectivity. These improvements have been rationalized using molecular modeling techniques. The expected functional selectivity in cells was also observed for both a SIRT1 and a SIRT2 selective analog.
• PYRIMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE
  申请人：The University Court of the University of Dundee

  公开号：EP2344462A1

  公开（公告）日：2011-07-20
• PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE
  申请人：The University Court of the University of Dundee

  公开号：EP2344462B1

  公开（公告）日：2016-05-18
• Compounds
  申请人：Westwood Nicholas James

  公开号：US20110245282A1

  公开（公告）日：2011-10-06

  The invention provides a compound according to formula (I): wherein: X is O or S; Y is O or S; each Ar and Ar′ is independently a mono-, bi- or tricyclic aryl or heteroaryl group optionally substituted with one or more substituents selected from halo, alkyl, aryl, heteroaryl, hydroxyl, nitro, amino, alkoxy, alkylthio, cyano, thio, ester, acyl and amido; each R 2 is independently hydrogen, halo, alkyl, aryl, heteroaryl, hydroxyl, nitro, amino, alkoxy, alkylthio, cyano and thio; and R 1 is as defined herein, or a physiologically acceptable salt, solvate, ester, amide or other physiologically functional derivative thereof.